Endocyte (ECYT) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	ENDOCYTE INC
Entity Central Index Key	1,235,007
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ecyt
Entity Common Stock, Shares Outstanding		42,263,069

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 26,588,400	$ 15,431,622
Short-term investments	128,020,599	158,168,832
Receivables	2,469	8,678
Prepaid expenses	968,185	772,579
Other assets	259,788	493,863
Total current assets	155,839,441	174,875,574
Property and equipment, net	3,506,192	3,398,398
Other noncurrent assets	61,496	111,605
Total assets	159,407,129	178,385,577
Current liabilities:
Accounts payable	1,360,079	1,262,565
Accrued wages and benefits	1,677,090	3,272,237
Accrued clinical trial expenses	885,220	804,066
Accrued expenses and other liabilities	621,707	850,125
Total current liabilities	4,544,096	6,188,993
Other liabilities, net of current portion	11,483	18,503
Deferred revenue, net of current portion	806,944	831,944
Total liabilities	5,362,523	7,039,440
Stockholders’ equity:
Common stock: $0.001 par value, 100,000,000 shares authorized; 42,034,733 and 42,252,598 shares issued and outstanding at December 31, 2015 and June 30, 2016	42,253	42,035
Additional paid-in capital	387,756,495	381,118,489
Accumulated other comprehensive (loss) income	96,246	(79,399)
Retained deficit	(233,850,388)	(209,734,988)
Total stockholders’ equity	154,044,606	171,346,137
Total liabilities and stockholders’ equity	$ 159,407,129	$ 178,385,577

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	42,252,598	42,034,733
Common stock, shares outstanding	42,252,598	42,034,733

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Collaboration revenue	$ 12,500	$ 12,500	$ 25,000	$ 25,000
Total revenue	12,500	12,500	25,000	25,000
Operating expenses:
Research and development	6,787,341	6,723,950	13,318,894	13,341,258
General and administrative	7,394,473	4,070,589	11,214,231	8,430,505
Total operating expenses	14,181,814	10,794,539	24,533,125	21,771,763
Loss from operations	(14,169,314)	(10,782,039)	(24,508,125)	(21,746,763)
Other income (expense), net:
Interest income, net	207,514	184,494	397,049	336,965
Other expense, net	(860)	(6,573)	(4,324)	(64,149)
Net loss	$ (13,962,660)	$ (10,604,118)	$ (24,115,400)	$ (21,473,947)
Net loss per share -basic and diluted (in dollars per share)	$ (0.33)	$ (0.25)	$ (0.57)	$ (0.51)
Items included in other comprehensive income (loss):
Unrealized loss on foreign currency translation		$ (1,597)		$ (1,281)
Unrealized gain (loss) on available-for-sale securities	$ 65,509	(17,448)	$ 175,645	117,068
Other comprehensive income (loss)	65,509	(19,045)	175,645	115,787
Comprehensive loss	$ (13,897,151)	$ (10,623,163)	$ (23,939,755)	$ (21,358,160)
Weighted-average number of common shares used in net loss per share calculation - basic and diluted (in shares)	42,178,537	41,939,052	42,144,182	41,898,702

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2016 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2015	$ 42,035	$ 381,118,489	$ (79,399)	$ (209,734,988)	$ 171,346,137
Balances (in shares) at Dec. 31, 2015	42,034,733
Exercise of stock options	$ 56	109,251			109,307
Exercise of stock options (in shares)	56,417
Stock-based compensation	$ 117	6,390,875			6,390,992
Stock-based compensation (in shares)	116,812
Employee stock purchase plan	$ 45	137,880			137,925
Employee stock purchase plan (in shares)	44,636
Net loss				(24,115,400)	(24,115,400)
Unrealized gain on securities			175,645		175,645
Balances at Jun. 30, 2016	$ 42,253	$ 387,756,495	$ 96,246	$ (233,850,388)	$ 154,044,606
Balances (in shares) at Jun. 30, 2016	42,252,598

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Net loss	$ (24,115,400)	$ (21,473,947)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	444,396	442,986
Stock-based compensation	6,549,276	3,533,936
Loss on disposal of property and equipment		1,106
Accretion of bond premium	268,695	713,939
Change in operating assets and liabilities:
Receivables	240,285	722,855
Prepaid expenses and other assets	85,334	(361,415)
Accounts payable	(219,119)	170,661
Accrued wages, benefits and other liabilities	(1,749,432)	(1,735,378)
Deferred revenue	(25,000)	(25,000)
Net cash used in operating activities	(18,520,965)	(18,010,257)
Investing activities
Purchases of property and equipment	(466,388)	(94,720)
Purchases of investments	(88,909,817)	(34,703,423)
Proceeds from sale and maturities of investments	118,965,000	34,866,376
Net cash provided by investing activities	29,588,795	68,233
Financing activities
Stock repurchase	(158,284)	(57,274)
Proceeds from the exercise of stock options	109,307	333,128
Proceeds from stock purchases under employee stock purchase plan	137,925	169,952
Net cash provided by financing activities	88,948	445,806
Effect of exchange rate		(1,281)
Net increase (decrease) in cash and cash equivalents	11,156,778	(17,497,499)
Cash and cash equivalents at beginning of period	15,431,622	45,533,443
Cash and cash equivalents at end of period	$ 26,588,400	$ 28,035,944

Nature of Business and Organiza

Nature of Business and Organization	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Nature of Business and Organization Endocyte, Inc. (the “Company”) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses its proprietary technology to create novel small molecule drug conjugates (“SMDCs”), and companion imaging agents. The SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with a highly active drug at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore most likely to benefit from treatment. The Company had two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe GmbH, which were formed to assist with the administration of applications with the European Commission (“EC”) and commercial pre-launch activities in Europe. The applications were withdrawn in May 2014 and the commercial pre-launch activities in Europe ceased. The Company dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated for 2015. The condensed financial statements for the three and six months ended June 30, 2016 include only the accounts of Endocyte, Inc. as the Company dissolved Endocyte Europe GmbH and Endocyte Europe B.V. in the fourth quarter of 2015 and the first quarter of 2016, respectively. There were no intercompany balances as of June 30, 2016 . The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2016 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission. Segment Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company had performed clinical trials globally and established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial pre-launch activities in Europe. The applications filed in Europe were withdrawn in May 2014 and the pre-launch activities in Europe ceased. The Company dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts may differ from those estimates. Cash and Cash Equivalents The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager. Investments Investments consist primarily of investments in U.S. Treasuries, U.S. government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. U.S. government agency investments relate to investments in Fannie Mae, Freddie Mac and Federal Home Loan Bank. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for- sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expensed over the term of the security. Revenue Recognition The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Upfront payments for licensing the Company’s intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue on the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered. In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. In the event of an early termination of a collaboration agreement, any deferred revenue is recognized in the period in which all obligations of the Company under the agreement have been fulfilled. Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e., not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone. Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company’s products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and a collaborator may share profit, the revenue would be recorded in the period earned. The Company often is required to make estimates regarding drug development and commercialization timelines for compounds being developed pursuant to a collaboration agreement. Because the drug development process is lengthy and the Company’s collaboration agreements typically cover activities over several years, this approach often results in the deferral of significant amounts of revenue into future periods. In addition, because of the many risks and uncertainties associated with the development of drug candidates, the Company’s estimates regarding the period of performance may change in the future. Any change in the Company’s estimates or a termination of the arrangement could result in substantial changes to the period over which the revenues are recognized. Research and Development Expenses Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, depreciation, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. In the event that a clinical trial is terminated early, the Company records, in the period of termination, an accrual for the estimated remaining costs to complete the trial. Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements . Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development expenses and are expensed over the service period based upon the level of services provided. As of June 30, 2016 , the Company had approximately $0.5 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets. Stock-Based Compensation The Company accounts for its stock-based compensation pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant, service-based restricted stock units (“RSUs”), shares available for purchase under the Company’s 2010 Employee Stock Purchase Plan (“ESPP”), and previously included performance-based RSUs (“PRSUs”). For PRSUs issued by the Company, stock-based compensation expense would have been recognized if the Company had determined that it was probable that the performance conditions would be achieved. All PRSUs expired in the three months ended June 30, 2016. For RSUs issued by the Company, stock-based compensation expense is recognized ratably over the service period. The Company recognizes compensation cost based on the grant-date fair value estimated in accordance with the provisions of ASC 718. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs, RSUs and shares to be purchased under the ESPP are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Common stock equivalents As of June 30, 2015 and 2016, the following number of potential common stock equivalents were outstanding: As of June 30, 2015 2016 Outstanding common stock options Outstanding warrants Outstanding PRSUs — Outstanding RSUs Shares to be purchased under the ESPP Total These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3. New Accounting Pronouncements Recently Issued Accounting Standards In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting , an update to ASC Topic 718, Stock Compensation . This guidance involves improving several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and the forfeiture rate calculation. This update is effective for the Company for interim and annual reporting periods beginning January 1, 2017 unless it elects early adoption. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases , an update to ASC Topic 842, Leases . This guidance requires lessees to recognize leases as assets and liabilities on their balance sheets but recognize expenses on their income statements in a manner similar to the current accounting guidance. For lessors, the guidance also modifies the classification criteria and the accounting for sales-type and direct finance leases. This update is effective for the Company for interim and annual reporting periods beginning January 1, 2019 unless it elects early adoption. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements — Going Concern , which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and provide related footnote disclosures. This guidance is effective for the Company for interim and annual reporting periods beginning on or after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The standard allows for either a full retrospective or modified retrospective transition method. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. Under ASU 2014-09, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In order to do so, an entity would follow the five-step process for in-scope transactions: 1) identify the contract with a customer, 2) identify the separate performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the separate performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year. Therefore, ASU 2014-09 will become effective for the Company for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, but not any earlier than the original effective date of December 15, 2016. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. In April 2016, the FASB issued ASU 2016-10, an update to Topic 606, which clarifies how entities should identify performance obligations and evaluate licensing. In May 2016, the FASB issued ASU 2016-12, an update to Topic 606, which clarifies guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Other Comprehensive Income (Loss) [Text Block]	4. Other Comprehensive Income (Loss) The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for three months ended June 30, 2015 and 2016 : Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at March 31, 2015 $ $ $ Unrealized loss Net amount reclassified to net loss — Other comprehensive loss Balance at June 30, 2015 $ $ $ Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at March 31, 2016 $ — $ $ Unrealized gain — Net amount reclassified to net loss — — — Other comprehensive income — Balance at June 30, 2016 $ — $ $ The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for six months ended June 30, 2015 and 2016 : Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at December 31, 2014 $ $ $ Unrealized gain (loss) Net amount reclassified to net loss — Other comprehensive income (loss) Balance at June 30, 2015 $ $ $ Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at December 31, 2015 $ — $ $ Unrealized gain — Net amount reclassified to net loss — — — Other comprehensive income — Balance at June 30, 2016 $ — $ $ The assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows, which results in translation adjustments being made in stockholders’ equity rather than to net loss.

Investments

Investments	6 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	5. Investments The Company applies the fair value measurement and disclosure provisions of ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Investments consist primarily of investments with original maturities greater than three months, but no longer than 24 months when purchased. ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon the transparency of inputs (observable and unobservable) to the valuation of an asset or liability as of the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy: Level 1 — Valuation is based on quoted prices for identical assets or liabilities in active markets. Level 2 — Valuation is based on quoted prices for similar assets or liabilities in active markets, or other inputs that are observable for the asset or liability, either directly or indirectly, for the full term of the financial instrument. Level 3 — Valuation is based upon other unobservable inputs that are significant to the fair value measurement. The fair value of the Company’s fixed income securities is based on a market approach using quoted market values. The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2015 : Fair Value Description Cost Level 1 Level 2 (Carrying Value) Cash Cash $ $ $ — $ Cash equivalents FDIC insured deposits and money market funds — Cash and cash equivalents $ $ $ — $ Short-term investments (due within 1 year) U.S. government treasury obligations $ $ $ — $ U.S. government agency obligations — Corporate obligations — Total short-term investments $ $ $ $ The following table summarizes the fair value of cash and cash equivalents and investments as of June 30, 2016 : Fair Value Description Cost Level 1 Level 2 (Carrying Value) Cash Cash $ $ $ — $ Cash equivalents FDIC insured deposits and money market funds — Cash and cash equivalents $ $ $ — $ Short-term investments (due within 1 year) U.S. government treasury obligations $ $ $ — $ U.S. government agency obligations — Corporate obligations — Total short-term investments $ $ $ $ All securities held at December 31, 2015 and June 30, 2016 , were classified as available-for-sale as defined by ASC 320. Total unrealized gross gains were $5,690 and $96,497 as of December 31, 2015 and June 30, 2016 , respectively. Total unrealized gross losses were $85,089 and $251 as of December 31, 2015 and June 30, 2016 , respectively. The Company does not consider any of the unrealized losses to be other-than-temporary impairments because the Company has the intent and ability to hold investments until they recover in value. Total realized gross gains were $1,667 for the six months ended June 30, 2015. There were no realized gross gains for the six months ended June 30, 2016. There were no total realized gross losses for the six months ended June 30, 2015 or 2016 .

Collaborations

Collaborations	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	6. Collaborations NMP License and Commercialization Agreement In August 2013, the Company entered into a license and commercialization agreement with Nihon Medi-Physic Co., LTD. (“NMP”) that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. The Company received a $1.0 million non-refundable upfront payment, is eligible for up to $4.5 million based on the successful achievement of regulatory goals for etarfolatide in five different cancer indications and is eligible to receive double-digit percentage royalties on sales of etarfolatide in Japan. For revenue recognition purposes, the Company viewed the agreement with NMP as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company has identified the deliverables related to the collaboration with NMP, which include the license granted to NMP, as well as the obligation to provide preclinical and clinical supply of etarfolatide, to provide rights to NMP if a product is developed that replaces etarfolatide, the obligation for the Company to provide clinical data to NMP during the contract period and the coordination of development and commercialization efforts between the Company for vintafolide and NMP for etarfolatide in Japan. The Company’s deliverables will be accounted for as a single unit of account, therefore the non-refundable upfront payment is being recognized on a straight-line basis over the performance period. This determination was made because the successful development of etarfolatide in Japan requires the ongoing participation by the Company, including the development of the related therapeutic drug, vintafolide. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2033, the estimated termination date of the contract which is when the Company’s performance obligations will be completed. Any significant changes in the timing of the performance period could result in a change in the revenue recognition period. The Company had deferred revenue related to the agreement of approximately $0.9 million at June 30, 2016 . Subsequent to the inception of the NMP arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. The arrangement with NMP includes milestone payments of up to approximately $4.5 million and the milestones are based on the commencement of clinical trials in Japan for specific and non-specific indications and filing for approval in Japan for specific and non-specific indications. The Company evaluated each of these milestone payments and believes that all of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met because the Company must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. To date, the products have not been approved in Japan and no revenue has been recognized related to the regulatory milestones or royalties. NMP has the right to terminate the collaboration agreement on 90 days notice prior to the first commercial sale in Japan and six months notice after the first commercial sale in Japan. NMP also has the right to terminate the agreement on six months notice if the Company fails to launch vintafolide after receiving regulatory approval in Japan. NMP and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. Upon termination of the agreement depending on the circumstances, the parties have varying rights and obligations with respect to licensing and related regulatory materials and data.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. Stockholders’ Equity (Deficit) Stock-Based Compensation Plans The Company has had stock-based compensation plans since 1997. The awards made under the plans adopted in 1997 and 2007 consisted of stock options. The 2010 Equity Incentive Plan (the “2010 Plan”), which is the only plan under which awards may currently be made, authorizes awards in the form of stock options, stock appreciation rights, restricted stock, RSUs, PRSUs and performance units and performance shares. Awards under the 2010 Plan may be made to employees, directors and certain consultants as determined by the compensation committee of the board of directors. There were 9,742,563 and 11,003,563 shares of common stock authorized and reserved under these plans at December 31, 2015 and June 30, 2016 , respectively. Stock Options Under the various plans, employees have been granted incentive stock options, while directors and consultants have been granted non-qualified options. The plans allow the holder of an option to purchase common stock at the exercise price, which was at or above the fair value of the Company’s common stock on the date of grant. Generally, options granted under the 1997 and 2007 plans in connection with an employee’s commencement of employment vest over a four -year period with one -half of the shares subject to the grant vesting after two years of employment and remaining options vesting monthly over the remainder of the four-year period. Options granted under the 1997 and 2007 plans for performance or promotions vest monthly over a four -year period. Generally, options granted under the 2010 Plan vest annually over a three -year or four -year period. Unexercised stock options terminate on the tenth anniversary date after the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. The Company utilizes a Black-Scholes option-pricing model to estimate the value of stock options. The Black-Scholes model allows the use of a range of assumptions related to volatility, risk-free interest rate, employee exercise behavior and dividend yield. Expected volatilities used in the model beginning in 2015 were based on historical volatility of the Company’s stock prices. Due to insufficient history as a public company, the Company is using the “simplified” method for “plain vanilla” options to estimate the expected term of the stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate assumption is derived from the weighted-average yield of a U.S. Treasury security with the same term as the expected life of the options, and the dividend yield assumption is based on historical experience and the Company’s estimate of future dividend yields. The weighted-average value of the individual options granted during the three and six months ended June 30, 2015 and 2016 were determined using the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Expected volatility % % % % Risk-free interest rate % % % % Weighted-average expected life (in years) Dividend yield % % % % The Company executed a Separation Agreement and Release of Claims with its former Chief Executive Officer, P. Ron Ellis, in connection with his resignation from the Company in the three months ended June 30, 2016. Under this agreement and Mr. Ellis’ original Severance Agreement, the Company incurred additional stock compensation expense of $2.8 million related to the modification of Mr. Ellis’ options and RSUs. The vesting of each stock option and RSU, other than fully vested awards, was modified and the exercise period of each stock option was extended. In determining the additional expense related to the modification of awards, the company revalued the modified options in accordance with ASC 718 using the Black-Scholes model. The Company’s stock option activity and related information are summarized as follows: Weighted-Average Remaining Weighted-Average Contractual Term Aggregate Options Exercise Price (In Years) Intrinsic Value Outstanding at January 1, 2016 $ Granted during period Exercised during period Expired during period Forfeited during period — — Outstanding at March 31, 2016 $ $ Exercisable at March 31, 2016 $ $ Outstanding at April 1, 2016 Granted during period Exercised during period Expired during period — — Forfeited during period Outstanding at June 30, 2016 $ $ Exercisable at June 30, 2016 $ $ As of June 30, 2016 , the total remaining unrecognized compensation cost, net of forfeitures, related to stock options granted was $6.6 million, which is expected to be recognized over a weighted average period of approximately 1.5 years. Restricted Stock Units In May 2011, the Company adopted and granted awards under a performance-based RSU program (the “2011 PRSU Program”) under the 2010 Plan. As of June 30, 2016, the performance deadline of May 26, 2016 had passed and all PRSU awards had expired. Each unit represented an amount equal to one share of the Company’s common stock. The RSUs are service-based awards that will vest and be paid in the form of one share of the Company’s common stock for each RSU, generally in three or four equal annual installments beginning on the first anniversary of the date of grant of the RSU. As of June 30, 2016 , the Company had 416,244 RSU awards outstanding. As of June 30, 2016 , the total remaining unrecognized compensation cost, net of forfeitures, related to RSUs was $1.6 million, which is expected to be recognized over a weighted average period of approximately 1.6 years. Please refer to the Stock Options section in Note 7 – Stockholders Equity (Deficit) regarding additional stock compensation expense incurred in connection with the resignation of the Company’s former Chief Executive Officer, P. Ron Ellis, in the six months ended June 30, 2016. The following table sets forth the number of RSUs that were granted, vested and forfeited in the period indicated: Restricted Weighted-Average Stock Grant Units Date Fair Value Outstanding at January 1, 2016 $ Granted during period Vested during period Forfeited during period — — Outstanding at March 31, 2016 $ Outstanding at April 1, 2016 $ Granted during period Vested during period Forfeited during period Outstanding at June 30, 2016 $ Employee Stock Purchase Plan At January 1, 2016, 911,725 common shares were available for issuance under the ESPP. Shares may be issued under the ESPP twice a year. In the year ended December 31, 2015 , plan participants purchased 74,805 shares of common stock under the ESPP at an average purchase price of $4.08 per share. In the three and six months ended June 30, 2016 plan participants purchased 44,636 shares of common stock under the ESPP at an average purchase price of $3.09 per share. At June 30, 2016, 867,089 shares were available for issuance under the ESPP.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	8. Income Taxes The Company accounts for income taxes under the liability method in accordance with the provisions of ASC Topic 740, Income Taxes . The Company recognizes future tax benefits, such as net operating losses, to the extent those benefits are expected to be realized in future periods. Due to uncertainty surrounding the realization of its deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. The Company experienced a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code in August 2011. As a result, the future use of its net operating losses and credit equivalents is currently limited to approximately $201.9 million for 2016 and $16.8 million for 2017. Any available but unused amounts in 2016 will become available for use in 2017, subject to certain limitations. Utilization of these net operating loss carryforwards would require the Company to generate future taxable income prior to their expiration. Furthermore, the utilization of the net operating loss carryforwards could be limited beyond the Company's generation of taxable income if a change in the underlying ownership of the Company's common stock has occurred, resulting in a limitation on the amounts that could be utilized in any given period under Section 382 of the Code.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies On June 24, 2014, a complaint in a securities class action lawsuit was filed against the Company and one of its former officers and directors in the United States District Court for the Southern District of Indiana under the following caption: Tony Nguyen, on Behalf of Himself and All Others Similarly Situated v. Endocyte, Inc. and P. Ron Ellis (the “Nguyen Litigation”). On July 13, 2014, a nearly identical complaint in a securities class action lawsuit was filed against the Company and one of its former officers and directors in the United States District Court for the Southern District of Indiana under the following caption: Vivian Oh Revocable Trust, Individually and on Behalf of All Others Similarly Situated v. Endocyte, Inc. and P. Ron Ellis (the “Oh Litigation”). On September 22, 2014, the court named a lead plaintiff (“Lead Plaintiff”) and consolidated the Nguyen Litigation and the Oh Litigation under the following caption: Gopichand Vallabhaneni v. Endocyte, Inc. and P. Ron Ellis (the “Vallabhaneni Litigation”). On November 17, 2014, Lead Plaintiff filed a consolidated amended securities class action complaint (the “Amended Complaint”) against the Company, P. Ron Ellis, Beth Taylor, Michael A. Sherman, John C. Aplin, Philip S. Low, Keith E. Brauer, Ann F. Hanham, Marc Kozin, Peter D. Meldrum, Fred A. Middleton, Lesley Russell (the “Individual Defendants” and collectively with the Company, the “Endocyte Defendants”), and Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. (the “Underwriter Defendants”). The court dismissed the lawsuit without prejudice on January 4, 2016, but granted Lead Plaintiff until February 1, 2016 to demonstrate sufficient facts to justify an amended pleading. Lead Plaintiff did not respond, and on February 2, 2016, the court amended the dismissal to be with prejudice and a final order was so entered. Lead Plaintiff appealed the final judgment on March 1, 2016. On March 31, 2016, the appeal was voluntarily dismissed, with prejudice. On September 23, 2014, a complaint in a shareholder derivative lawsuit was filed against all but one of the Company’s current directors and one of its former directors in the United States District Court for the Southern District of Indiana under the following caption: William Moore, Derivatively on Behalf of Nominal Defendant Endocyte, Inc. v. John C. Aplin, et al. (the “Moore Litigation”). The Company was named as a nominal defendant in the case. On October 31, 2014, a complaint in a shareholder derivative lawsuit nearly identical to the Moore Litigation was filed against all but one of the Company’s current directors and one of its former directors in the United States District Court for the Southern District of Indiana under the following caption: Victor Veloso, Derivatively on Behalf of Endocyte, Inc. v. John C. Aplin, et al. (the “Veloso Litigation”). The Company was named as a nominal defendant in the case. On December 31, 2014, the court appointed co-lead counsel and consolidated the Moore Litigation with the Veloso Litigation under the following caption: In re Endocyte, Inc. Derivative Litigation (the “Endocyte Derivative Litigation”). The lawsuit was voluntarily dismissed without prejudice on April 19, 2016. On November 6, 2014, a complaint was filed against the Company, one of its current executive officers, one of its former executive officers, Merck and one of Merck’s officers in the Superior Court of Tippecanoe County, Indiana under the following caption: Mohamad Hage and Jamele Hage v. Endocyte, Inc., P. Ron Ellis, Mike A. Sherman, Eric Rubin and Merck & Co., Inc. (the “Hage Litigation”). On January 9, 2015, the defendants filed a Motion to Stay the Proceeding or in the Alternative to Stay Discovery (the “Motion to Stay”). A hearing on the Motion to Stay was held on February 19, 2015. On March 20, 2015, the court ruled to stay the case pending final resolution of the Vallabhaneni Litigation. The plaintiffs sought an interlocutory appeal to which the Company opposed. On May 22, 2015, the court denied the interlocutory appeal motion. After a status conference hearing on August 13, 2015, where plaintiffs sought to lift the stay, the court, on September 20, 2015, continued the stay in accordance with its March 20, 2015 ruling. Another status conference hearing was held on March 3, 2016. On July 21, 2016, the lawsuit was voluntarily dismissed, with prejudice.

Restructuring Costs

Restructuring Costs	6 Months Ended
	Jun. 30, 2016
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	10. Restructuring Costs The Company terminated the PROCEED trial in May 2014 after the interim futility analysis indicated that vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival for the treatment of platinum-resistant ovarian cancer. As a result, the Company recorded a charge of $4.1 million for remaining expenses of the PROCEED trial, including site close-out expenses, in the year ended December 31, 2014. At June 30, 2016 , the Company had a clinical trial accrual balance related to the PROCEED trial termination of $23,600 , which is expected to be fully paid in 2016. The following table summarizes the restructuring accruals for the three and six months ended June 30, 2016 : PROCEED Trial Termination Accrual Balance at March 31, 2016 $ Amounts paid in the three months ended June 30, 2016 Balance, June 30, 2016 $ PROCEED Trial Termination Accrual Balance, December 31, 2015 $ Amounts paid in the six months ended June 30, 2016 Balance, June 30, 2016 $

Significant Accounting Polici17

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated for 2015. The condensed financial statements for the three and six months ended June 30, 2016 include only the accounts of Endocyte, Inc. as the Company dissolved Endocyte Europe GmbH and Endocyte Europe B.V. in the fourth quarter of 2015 and the first quarter of 2016, respectively. There were no intercompany balances as of June 30, 2016 . The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2016 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company had performed clinical trials globally and established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial pre-launch activities in Europe. The applications filed in Europe were withdrawn in May 2014 and the pre-launch activities in Europe ceased. The Company dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts may differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
Investment, Policy [Policy Text Block]	Investments Investments consist primarily of investments in U.S. Treasuries, U.S. government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. U.S. government agency investments relate to investments in Fannie Mae, Freddie Mac and Federal Home Loan Bank. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for- sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expensed over the term of the security.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Upfront payments for licensing the Company’s intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue on the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered. In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. In the event of an early termination of a collaboration agreement, any deferred revenue is recognized in the period in which all obligations of the Company under the agreement have been fulfilled. Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e., not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone. Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company’s products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and a collaborator may share profit, the revenue would be recorded in the period earned. The Company often is required to make estimates regarding drug development and commercialization timelines for compounds being developed pursuant to a collaboration agreement. Because the drug development process is lengthy and the Company’s collaboration agreements typically cover activities over several years, this approach often results in the deferral of significant amounts of revenue into future periods. In addition, because of the many risks and uncertainties associated with the development of drug candidates, the Company’s estimates regarding the period of performance may change in the future. Any change in the Company’s estimates or a termination of the arrangement could result in substantial changes to the period over which the revenues are recognized.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, depreciation, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. In the event that a clinical trial is terminated early, the Company records, in the period of termination, an accrual for the estimated remaining costs to complete the trial. Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements . Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development expenses and are expensed over the service period based upon the level of services provided. As of June 30, 2016 , the Company had approximately $0.5 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for its stock-based compensation pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant, service-based restricted stock units (“RSUs”), shares available for purchase under the Company’s 2010 Employee Stock Purchase Plan (“ESPP”), and previously included performance-based RSUs (“PRSUs”). For PRSUs issued by the Company, stock-based compensation expense would have been recognized if the Company had determined that it was probable that the performance conditions would be achieved. All PRSUs expired in the three months ended June 30, 2016. For RSUs issued by the Company, stock-based compensation expense is recognized ratably over the service period. The Company recognizes compensation cost based on the grant-date fair value estimated in accordance with the provisions of ASC 718.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs, RSUs and shares to be purchased under the ESPP are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Common stock equivalents As of June 30, 2015 and 2016, the following number of potential common stock equivalents were outstanding: As of June 30, 2015 2016 Outstanding common stock options Outstanding warrants Outstanding PRSUs — Outstanding RSUs Shares to be purchased under the ESPP Total These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings.

Significant Accounting Polici18

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of June 30, 2015 2016 Outstanding common stock options Outstanding warrants Outstanding PRSUs — Outstanding RSUs Shares to be purchased under the ESPP Total

Other Comprehensive Income (L19

Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2016
Other Comprehensive Income (Loss), Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for three months ended June 30, 2015 and 2016 : Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at March 31, 2015 $ $ $ Unrealized loss Net amount reclassified to net loss — Other comprehensive loss Balance at June 30, 2015 $ $ $ Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at March 31, 2016 $ — $ $ Unrealized gain — Net amount reclassified to net loss — — — Other comprehensive income — Balance at June 30, 2016 $ — $ $ The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for six months ended June 30, 2015 and 2016 : Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at December 31, 2014 $ $ $ Unrealized gain (loss) Net amount reclassified to net loss — Other comprehensive income (loss) Balance at June 30, 2015 $ $ $ Foreign Accumulated Currency Unrealized Net Other Translation Gains (Losses) Comprehensive Gains (Losses) on Securities Gains (Losses) Balance at December 31, 2015 $ — $ $ Unrealized gain — Net amount reclassified to net loss — — — Other comprehensive income — Balance at June 30, 2016 $ — $ $

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Schedule Of Cash And Cash Equivalents And Short Term Investments [Table Text Block]	The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2015 : Fair Value Description Cost Level 1 Level 2 (Carrying Value) Cash Cash $ $ $ — $ Cash equivalents FDIC insured deposits and money market funds — Cash and cash equivalents $ $ $ — $ Short-term investments (due within 1 year) U.S. government treasury obligations $ $ $ — $ U.S. government agency obligations — Corporate obligations — Total short-term investments $ $ $ $ The following table summarizes the fair value of cash and cash equivalents and investments as of June 30, 2016 : Fair Value Description Cost Level 1 Level 2 (Carrying Value) Cash Cash $ $ $ — $ Cash equivalents FDIC insured deposits and money market funds — Cash and cash equivalents $ $ $ — $ Short-term investments (due within 1 year) U.S. government treasury obligations $ $ $ — $ U.S. government agency obligations — Corporate obligations — Total short-term investments $ $ $ $

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Expected volatility % % % % Risk-free interest rate % % % % Weighted-average expected life (in years) Dividend yield % % % %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted-Average Remaining Weighted-Average Contractual Term Aggregate Options Exercise Price (In Years) Intrinsic Value Outstanding at January 1, 2016 $ Granted during period Exercised during period Expired during period Forfeited during period — — Outstanding at March 31, 2016 $ $ Exercisable at March 31, 2016 $ $ Outstanding at April 1, 2016 Granted during period Exercised during period Expired during period — — Forfeited during period Outstanding at June 30, 2016 $ $ Exercisable at June 30, 2016 $ $
Schedule of Nonvested Share Activity [Table Text Block]	Restricted Weighted-Average Stock Grant Units Date Fair Value Outstanding at January 1, 2016 $ Granted during period Vested during period Forfeited during period — — Outstanding at March 31, 2016 $ Outstanding at April 1, 2016 $ Granted during period Vested during period Forfeited during period Outstanding at June 30, 2016 $

Restructuring Costs (Tables)

Restructuring Costs (Tables)	6 Months Ended
	Jun. 30, 2016
Restructuring Costs [Abstract]
Restructuring and Related Costs [Table Text Block]	PROCEED Trial Termination Accrual Balance at March 31, 2016 $ Amounts paid in the three months ended June 30, 2016 Balance, June 30, 2016 $ PROCEED Trial Termination Accrual Balance, December 31, 2015 $ Amounts paid in the six months ended June 30, 2016 Balance, June 30, 2016 $

Nature of Business and Organi23

Nature of Business and Organization (Details)	6 Months Ended
	Jun. 30, 2016subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of wholly-owned subsidiaries in the process of being dissolved	2

Significant Accounting Polici24

Significant Accounting Policies (Details Textual) $ in Millions	Jun. 30, 2016USD ($)
Research and Development Arrangement [Member]
Significant Accounting Policies [Line Items]
Prepaid Expense and Other Assets, Noncurrent	$ 0.5

Significant Accounting Polici25

Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2016segmentshares	Jun. 30, 2015shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding	7,010,625	6,250,744
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of Operating Segments | segment	1
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding	6,555,769	5,658,201
Outstanding warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding	34,647	34,647
Outstanding PRSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding		217,247
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding	416,244	337,262
Shares To be Purchased Under The ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential Common Stock Equivalents, Outstanding	3,965	3,387

Other Comprehensive Income (L26

Other Comprehensive Income (Loss) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Comprehensive Income (Loss), Tax [Abstract]
Foreign Currency Translation Gains (Losses), Beginning balance		$ (50,276)		$ (50,592)
Foreign Currency Translation Gains (Losses), Unrealized gain (Loss)		(1,597)		(1,281)
Foreign Currency Translation Gains (Losses), Other comprehensive income (loss)		(1,597)		(1,281)
Foreign Currency Translation Gains (Losses), Ending balance		(51,873)		(51,873)
Unrealized Net Gains (Losses) on Securities, Beginning balance	$ 30,737	41,180	$ (79,399)	(93,336)
Unrealized Net Gains (Losses) on Securities, Unrealized gain (loss)	65,509	(17,485)	175,645	121,972
Unrealized Net Gains (Losses) on Securities, Net amount reclassified to net loss		37		(4,904)
Unrealized Net Gains (Losses) on Securities, Other comprehensive income (loss)	65,509	(17,448)	175,645	117,068
Unrealized Net Gains (Losses) on Securities, Ending balance	96,246	23,732	96,246	23,732
Accumulated Other Comprehensive Gains (Losses), Beginning balance	30,737	(9,096)	(79,399)	(143,928)
Accumulated Other Comprehensive Gains (Losses), Unrealized gain (loss)	65,509	(19,082)	175,645	120,691
Accumulated Other Comprehensive Gains (Losses), Net amount reclassified to net loss		37		(4,904)
Accumulated Other Comprehensive Gains (Losses), Other comprehensive income (loss)	65,509	(19,045)	175,645	115,787
Accumulated Other Comprehensive Gains (Losses), Ending balance	$ 96,246	$ (28,141)	$ 96,246	$ (28,141)

Investments (Details)

Investments (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Cash
Cash	$ 1,418,655	$ 5,154,191
Cash equivalents
Money market funds	25,169,745	10,277,431
Cash and cash equivalents	26,588,400	15,431,622	$ 28,035,944	$ 45,533,443
Short-term investments (due within 1 year)
Short-term investments, Fair Value	128,020,599	158,168,832
Short-term investments, Cost	127,924,353	158,248,231
U.S. government treasury obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	81,157,085	73,560,085
Short-term investments, Cost	81,068,038	73,593,081
U.S. government agency obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	15,981,770	55,670,043
Short-term investments, Cost	15,978,984	55,702,099
Corporate obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	30,881,744	28,938,704
Short-term investments, Cost	30,877,331	28,953,051
Fair Value, Inputs, Level 1 [Member]
Cash
Cash	1,418,655	5,154,191
Cash equivalents
Money market funds	25,169,745	10,277,431
Cash and cash equivalents	26,588,400	15,431,622
Short-term investments (due within 1 year)
Short-term investments, Fair Value	97,138,855	129,230,128
Fair Value, Inputs, Level 1 [Member] | U.S. government treasury obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	81,157,085	73,560,085
Fair Value, Inputs, Level 1 [Member] | U.S. government agency obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	15,981,770	55,670,043
Fair Value, Inputs, Level 2 [Member]
Short-term investments (due within 1 year)
Short-term investments, Fair Value	30,881,744	28,938,704
Fair Value, Inputs, Level 2 [Member] | Corporate obligations
Short-term investments (due within 1 year)
Short-term investments, Fair Value	$ 30,881,744	$ 28,938,704

Investments (Details Textual)

Investments (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Unrealized Gain on Securities	$ 96,497		$ 5,690
Unrealized Loss on Securities	251		$ 85,089
Realized Gain on Securities		$ 1,667
Realized Loss on Securities	$ 0	$ 0

Collaborations (Details Textual

Collaborations (Details Textual) - NMP [Member] - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Aug. 31, 2013	Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable Upfront Payments Received	$ 1
Deferred Revenue		$ 0.9
Potential Milestone Payments	$ 4.5
Period of time for termination notice to be given prior to the first commercial sale in Japan	90 days
Period of time for termination notice to be given after the first commercial sale in Japan	6 months
Period of time for termination notice to be given after Company receives regulatory approval in Japan but fails to launch the product	6 months
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential Milestone Payments		$ 4.5

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Mar. 31, 2016	Jan. 01, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	100,000,000	100,000,000	100,000,000
Stock Options
Unrecognized compensation cost, net of forfeitures	$ 6.6	$ 6.6
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 6 months
Employee Stock Purchase Plan (Abstract)
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 6.38	$ 6.38	$ 6.87	$ 6.43
P. Ron Ellis
Stock Options
Stock-based compensation expense	$ 2.8
1997 And 2007 Plans
Stock Options
Vesting period		4 years
1997 And 2007 Plans | First vesting after date of employment
Stock Options
Shares that will vest (as a percentage)		50.00%
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	11,003,563	11,003,563	9,742,563
Equity Incentive Plan 2010 [Member] | Minimum [Member]
Stock Options
Vesting period		3 years
Equity Incentive Plan 2010 [Member] | Maximum [Member]
Stock Options
Vesting period		4 years
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan (Abstract)
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.09	$ 3.09	$ 4.08
Stock Issued During Period, Shares, Employee Stock Purchase Plans	44,636	44,636	74,805
Common Stock, Capital Shares Reserved for Future Issuance	867,089	867,089			911,725
Vesting Based On Service | 1997 And 2007 Plans | First vesting after date of employment
Stock Options
Vesting period		2 years
Vesting Based On Performance | 1997 And 2007 Plans
Stock Options
Vesting period		4 years

Stockholders' Equity - weighted

Stockholders' Equity - weighted average assumptions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Equity [Abstract]
Expected volatility	97.80%	105.60%	99.10%	106.80%
Risk-free interest rate	1.55%	1.98%	1.48%	1.53%
Weighted-average expected life (in years)	8 years 4 months 24 days	8 years 6 months	6 years 7 months 6 days	6 years 4 months 24 days
Dividend yield	0.00%	0.00%	0.00%	0.00%

Stockholders' Equity - stock 32

Stockholders' Equity - stock option activity (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016
Equity [Abstract]
Options, Outstanding, Beginning Balance	6,479,347	5,686,815	5,686,815
Options, Granted during period	189,900	845,247
Options, Exercised during period	(7,538)	(48,879)
Options, Expired during period		(3,836)
Options, Forfeited during period	(105,940)
Options, Outstanding, Ending Balance	6,555,769	6,479,347	6,555,769
Options, Exercisable	4,637,674	4,171,230	4,637,674
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 6.43	$ 6.87	$ 6.87
Weighted Average Exercise Price, Granted during period	3.45	3.18
Weighted Average Exercise Price, Exercised during period	2.10	1.91
Weighted Average Exercise Price, Expired during period		7.34
Weighted Average Exercise Price, Forfeited during period	3.94
Weighted Average Exercise Price, Outstanding, Ending Balance	6.38	6.43	6.38
Weighted Average Exercise Price, Exercisable	$ 6.65	$ 6.62	$ 6.65
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance	6 years 7 months 6 days	6 years 9 months 15 days
Weighted Average Remaining Contractual Term, Exercisable	5 years 8 months 12 days	5 years 7 months 21 days
Aggregate Intrinsic Value, Outstanding, Ending Balance	$ 392,534	$ 308,641	$ 392,534
Aggregate Intrinsic Value, Exercisable	$ 372,270	$ 308,641	$ 372,270

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2011	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Restricted Stock (Abstract)
RSU awards outstanding		6,555,769	6,479,347	6,555,769	5,686,815
Weighted average period				1 year 6 months
RSUs [Member]
Restricted Stock (Abstract)
Number of shares of common stock to be paid upon vesting of RSU				1
RSU awards outstanding		416,244		416,244
Unrecognized compensation cost		$ 1.6		$ 1.6
Weighted average period				1 year 7 months 6 days
Restricted Stock Units
Outstanding at beginning of period		469,705	351,414	351,414
Restricted Stock Units, Granted during period		28,000	222,788
Restricted Stock Units, Vested during period		(60,603)	(104,497)
Restricted Stock Units, Forfeited during period		(20,858)
Outstanding at the end of the period		416,244	469,705	416,244
Weighted-Average Grant Date Fair Value
Beginning of period		$ 5.16	$ 7.03	$ 7.03
Weighted-Average Grant Date Fair Value, Granted during period		3.47	3.18
Weighted-Average Grant Date Fair Value, Vested during period		6.06	7.20
Weighted-Average Grant Date Fair Value, Forfeited during period		3.53
End of period		$ 5	$ 5.16	$ 5
Performance based Restricted Stock Units P R S Us [Member]
Restricted Stock (Abstract)
Number of shares of common stock to be paid upon vesting of RSU	1
Minimum [Member] | RSUs [Member] | Vesting Based On Service
Restricted Stock (Abstract)
Vesting period				3 years
Maximum [Member] | RSUs [Member] | Vesting Based On Service
Restricted Stock (Abstract)
Vesting period				4 years

Income Taxes (Details Textual)

Income Taxes (Details Textual) $ in Millions	Jun. 30, 2016USD ($)
For 2016 [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 201.9
For 2017 [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 16.8

Restructuring Costs (Details)

Restructuring Costs (Details) - Proceed Trial Termination [Member] - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Balance, (Opening)	$ 26,600	$ 46,600
Amounts Paid During The Period	(3,000)	(23,000)
Balance, (Closing)	$ 23,600	$ 23,600

Restructuring Costs (Details Te

Restructuring Costs (Details Textual) - Proceed Trial Termination [Member] - USD ($)	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, Total	$ 4,100,000
Clinical trial reserve balance		$ 23,600	$ 26,600	$ 46,600